AG-348
190097
Phase 1 small_molecule completed
Quick answer
AG-348 for Sickle Cell Disease is a Phase 1 program (small_molecule) at AGIOS PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AGIOS PHARMACEUTICALS, INC.
- Indication
- Sickle Cell Disease
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed